Small Cell Lung Cancer - Pipeline Insight, 2021

This “Small Cell Lung Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Small Cell Lung Cancer Understanding

Small Cell Lung Cancer: Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non-small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa. Symptoms of SCLC are chest pain, chronic cough, coughing up blood, difficulty breathing, facial swelling, fatigue, hoarseness, loss of appetite, swollen neck veins, weight loss, and wheezing. The standard treatment for first- and second-line management of small cell lung cancer (SCLC) is chemotherapy. Immunotherapy has also made progress in the treatment of SCLC including nivolumab, pembrolizumab, atezolizumab, and durvalumab.

"Small Cell Lung Cancer - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Small Cell Lung Cancer.

Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Small Cell Lung Cancer Emerging Drugs

AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Small Cell Lung Cancer

There are approx. 100+ key companies which are developing the therapies for Small Cell Lung Cancer. The companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Small Cell Lung Cancer drugs.

Small Cell Lung Cancer Report Insights

• Small Cell Lung Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Small Cell Lung Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Small Cell Lung Cancer drugs?
• How many Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascentage Pharma
• Merck & Co
• AstraZeneca
• Advenchen Laboratories
• GlaxoSmithKline
• Advanced Accelerator Applications
• Trillium Therapeutics
• Vernalis
• Oncoceutics
• NewBio Therapeutics
• Wigen Biomedicine
• Linton Pharm
• Carrick Therapeutics
• Xencor
• Jiangsu HengRui Medicine
• Aileron Therapeutics
• Roche
• Ipsen
• Celgene
• Lee's Pharmaceutical Limited
• AbbVie
• G1 Therapeutics
• Chipscreen Biosciences
• Luye Pharma Group
• Shanghai Henlius Biotech
• CSPC ZhongQi Pharmaceutical Technology
• Impact Therapeutics

Key Products

• APG-1252
• Pembrolizumab
• Olaparib
• Lucitanib
• Dostarlimab
• Lutetium-177 oxodotreotide
• Ontorpacept
• S 055746
• ONC 201
• NBT-558
• WJ-05129
• LP-003
• Samuraciclib
• XmAb18087
• SHR3162
• ALRN-6924
• Irinotecan sucrosofate
• CC-90011
• Gimatecan
• ABBV-011
• G1T28
• Chiauranib
• LY01610
• HLX10
• PLM60
• IMP4297